PAIN TRIGGERS
Companies refuse to disclose total shares outstanding or equity percentage for granted shares.
Lack of transparency on equity makes it hard to judge total compensation value.
SaaS· executive/director level candidates in biotech and pharmaPain 7.00/10WTP 7.0/10Market 6.0/10Validation 8.0Confidence 82%May 7, 2026
EquityPercent: Pre-Offer Cap Table Transparency for Biotech Execs
Startup offers state raw share grants without total shares outstanding or ownership percentage, making it impossible to assess true compensation value and creating high-risk career moves.
analyticsbiotechcompensationconsultantsequityexecutivesproductivityrecruitingsaasstartups
1
STAGE 01 · PROBLEM
Is the problem real?
CANONICAL PROBLEM
Startup job offers provide equity grants (e.g. number of shares) without disclosing total shares outstanding or percentage ownership, making it impossible for candidates to evaluate the real value of the compensation package.
FREQUENCY
Multiple repeated complaints in the post and comments.
INTENSITY
Users explicitly describe existing tools as bloated/overkill and mention workaround behavior.
EVIDENCE
Series A Biotech Offer Refuses to Disclose Equity Percentage - Advice (I will not promote)
startups2944
"150k shares without total shares outstanding is like telling someone they won coins at an arcade without saying the exchange rate"
comment150k shares without total shares outstanding is like telling someone they won coins at an arcade without saying the exchange rate 😭 For an Executive Director-level role, not disclosing even an approximate % ownership feels sketchy. One red flag alone maybe explainable, but combined with the written offer not matching the verbal one? Yeah turning it down was probably the right call.
"For an Executive Director-level role, not disclosing even an approximate % ownership feels sketchy."
comment150k shares without total shares outstanding is like telling someone they won coins at an arcade without saying the exchange rate 😭 For an Executive Director-level role, not disclosing even an approximate % ownership feels sketchy. One red flag alone maybe explainable, but combined with the written offer not matching the verbal one? Yeah turning it down was probably the right call.
2
STAGE 02 · CUSTOMER
Who feels this pain?
TARGET USERS
executive/director level candidates in biotech and pharmaBiotech/ Pharma Exec Job Seekers
Experienced directors and VPs leaving big pharma for post-Series A startups who need to quantify equity value before resigning stable roles.
Context
Accurately value equity compensation in startup offers, especially at executive/director levels after Series A, to decide whether to accept the role and leave a stable job.
Candidates turn down offers or walk away when transparency is refused.
Focus on cash compensation and bonuses instead of equity value.
Current Workarounds
Walking away from offers lacking disclosure
Relying on rough industry rules of thumb for share value
Focusing only on cash comp and ignoring equity
Asking personal networks or AI for conflicting estimates
3
STAGE 03 · MARKET
Where's the gap?
EXISTING SOLUTION GAPS
No standard policy or legal requirement forces disclosure of fully diluted shares or % at offer stage.
Reliance on AI advice or personal networks yields conflicting guidance.
Companies cite proprietary reasons or cap table complexity to avoid sharing details.
OPPORTUNITY & VALUE
Why Now
Multiple users and commenters confirm refusal to disclose total shares/% is common yet highly problematic at executive levels in biotech.
Value Proposition
Focused exclusively on pre-acceptance transparency for senior biotech roles rather than post-hire cap table management or general salary data.
Product Direction
A lightweight web platform where candidates upload offers and receive benchmarked equity valuation estimates plus templated negotiation requests that pressure companies to disclose fully diluted cap table data.
4
STAGE 04 · BUSINESS
How does it make money?
MONETIZATION
$99/moIndividual access with 3 active offers
Model
SaaS subscription
WILLINGNESS TO PAY
Candidates already walk away from opaque offers and treat equity as mission-critical at executive level; one successful negotiation can represent hundreds of thousands in value, making $99 trivial compared to the risk of misjudging a grant.
5
STAGE 05 · EXECUTION
How do you ship it?
MVP PLAN
“Know your real ownership percentage before you quit your day job.”
A lightweight web platform where candidates upload offers and receive benchmarked equity valuation estimates plus templated negotiation requests that pressure companies to disclose fully diluted cap table data.
Core Features
Anonymous offer upload with share grant + valuation inputs
Biotech-specific benchmark database of % ownership by role/stage
One-click negotiation email/Slack templates demanding % disclosure
Basic equity value calculator with dilution scenarios
Weekly Roadmap
1
W1-W2
Core offer upload and basic valuation calculator live.
- •Build anonymous offer intake form
- •Implement equity calculator with dilution assumptions
- •Create simple user dashboard
2
W3-W4
Benchmark database and templates functional.
- •Seed initial biotech benchmarks from public data
- •Build templated request generator
- •Add email export functionality
3
W5
Internal testing with 5-10 beta users and basic analytics.
- •Recruit beta testers from biotech networks
- •Polish UI/UX for mobile offer review
- •Add usage analytics
4
W6
Public launch with first paid subscribers.
- •Stripe integration for subscriptions
- •Launch post on r/biotech and LinkedIn
- •Track first 10 signups and conversions
Launch Strategy
Target biotech LinkedIn groups, r/biotech, and pharma-to-startup career communities with free valuation reports as lead magnet.
RISKS & ASSUMPTIONS
Top Risks
Data sparsity for benchmarks
Early benchmark database may lack sufficient biotech-specific post-Series A data, reducing perceived accuracy.
Candidate willingness to pay
Job seekers in transition may be price sensitive and prefer free workarounds or generalist tools.
Legal risk on templates
Negotiation templates requesting cap table details could be viewed as aggressive and trigger company pushback.
Low volume of target users
Executive biotech transitions are infrequent compared to general tech hiring.
6
STAGE 06 · DECISION
Should you build it?
NEED A CLEARER CALL?
Run an Investment Memo to get a structured Go / No-Go verdict, competitor landscape, unit economics, and a 90-day validation roadmap for this opportunity.
Generate an investment memoWhat this score means
This idea scores in the upper-middle range of opportunities surfaced by MonetScope, with a validation sub-score of 8/10 against 3 independently sourced evidence signals. A "promising" rating usually indicates a real pain has been detected and discussed in the open, but the pipeline did not find enough signal to flag it as urgent or high-frequency. These opportunities can still produce excellent businesses — they often correspond to "boring" problems that established players have ignored — but the founder should expect a longer customer-development cycle to confirm willingness to pay.
Why this matters for SaaS founders
It sits at the intersection of "analytics", "biotech", "compensation", which makes it relevant to a specific subset of founders rather than a generic horizontal opportunity. SaaS opportunities at this stage tend to win on the strength of their initial wedge — a single workflow that the target user runs every week, where the existing solution is either spreadsheets, a clunky incumbent feature, or a manual process they hate. The build cost is moderate; the distribution cost is everything. The MonetScope pipeline surfaces this category alongside other saas signals, which is why it appears here rather than in a generic "trending ideas" feed.
Scores are derived from real forum discussions across Reddit, Hacker News and X, weighted by evidence volume and signal quality. How scoring works
Frequently asked questions
Is "EquityPercent: Pre-Offer Cap Table Transparency for Biotech Execs" a real validated startup idea or just an AI-generated suggestion?
MonetScope does not generate ideas from a language model's imagination. Every opportunity on this site is anchored to specific source posts and comments from real public discussions — typically on Reddit, Hacker News, or X — where actual users describe the pain in their own words. The AI's role is structuring, scoring, and grouping those signals into a navigable opportunity, not inventing the problem.
How recent is the underlying data for analytics?
MonetScope's spider pipeline runs continuously and surfaces opportunities as new evidence accumulates. The "Updated" date in the header reflects the most recent re-scoring of this specific opportunity. Most saas opportunities visible in the public catalog draw from discussions in the last 30-60 days; older signals are de-prioritized because user pain shifts faster than most founders assume.
What's the difference between "overall score" and "validation score"?
Overall score is a composite across six dimensions — pain, urgency, willingness to pay, market size, defensibility, and execution ease — designed to give a single number for triage. Validation score is narrower: it asks "how cleanly does the same signal repeat across independent sources?" An opportunity can score high on overall but lower on validation when one or two large discussions dominate the evidence; conversely, validation can be high on a smaller-overall idea where the signal is consistent but the addressable market is modest.